FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bod Science's Free Cash Flow for the
six
months ended in Jun. 2025 was A$0.90 Mil. Bod Science's Revenue for the
six
months ended in Jun. 2025 was A$0.88 Mil. Therefore, Bod Science's FCF Margin % for the quarter that ended in Jun. 2025 was 101.81%.
The historical rank and industry rank for Bod Science's FCF Margin % or its related term are showing as below:
ASX:BOD'
s FCF Margin % Range Over the Past 10 Years
Min: -806.83 Med: -332.14 Max: 63.1
Current: 63.1
During the past 9 years, the highest FCF Margin % of Bod Science was 63.10%. The lowest was -806.83%. And the median was -332.14%.
ASX:BOD's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.445
vs ASX:BOD: 63.10
Bod Science FCF Margin % Related Terms
Bod Science FCF Margin % Historical Data
* Premium members only.
The historical data trend for Bod Science's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bod Science's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bod Science FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bod Science's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bod Science's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bod Science (ASX:BOD) has a FCF Margin % of 101.81% as of Jun. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bod Science and its competitors.
Is Bod Science's FCF Margin % too high?
Bod Science's current FCF Margin % is 101.81%. The Drug Manufacturers industry median FCF Margin % is 2.45. Bod Science's value of 101.81% is 4064% above this industry median. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's FCF Margin % compare to ZTS?
Bod Science's FCF Margin % of 101.81% can be compared against companies in the Drug Manufacturers industry. The industry median FCF Margin % is 2.45. Bod Science's value of 101.81% is 4064% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bod Science's current FCF Margin % of 101.81% is 4064% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bod Science and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bod Science's current FCF Margin % is 101.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current FCF Margin % of 101.81%. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current FCF Margin % is 101.81% and 4064% above the Drug Manufacturers industry median of 2.45. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current FCF Margin % is 101.81% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bod Science (ASX:BOD) Overvalued in 2026?
Based on GuruFocus' analysis, Bod Science stock appears to be undervalued.
The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.
Key valuation signals for ASX:BOD:
FCF Margin %: 101.81%
GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
Industry Position: 4064% above the Drug Manufacturers median
No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score
Get the complete analysis for ASX:BOD
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BOD has been successfully added to your 
